Drugs / intravenous immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01502267 | Jan 2010 → Jan 2014 | end stage renal failure | Seoul National University Hospital | Unknown | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous immunoglobulin | “Combination therapy of intravenous immunoglobulin (IVIG) and rituximab showed a good transplant rate in highly sensitized wait-listed patients for deceased donor kidney...” PMID 26844479 ↗ Feb 2016 |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01502267 ↗ |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin (IVIG)” PMID 26844479 ↗ Feb 2016 |
| Route | Intravenous | “intravenous immunoglobulin (IVIG)” PMID 26844479 ↗ Feb 2016 |